Dose-escalated radiotherapy with simultaneous integrated boost for bone metastases in selected patients with assumed favourable prognosis

1Agarawal JP, Swangsilpa T, van der Linden Y, Rades D, Jeremic B, Hoskin PJ. The role of external beam radiotherapy in the management of bone metastases. Clin Oncol (R Coll Radiol) 2006; 18: 747-60. doi: 10.1016/j. clon.2006.09.007 Agarawal JP Swangsilpa T van der Linden Y Rades D Jeremic B Hoskin PJ The role of external beam radiotherapy in the management of bone metastases Clin Oncol (R Coll Radiol) 2006 18 747 60 10.1016/j.clon.2006.09.00717168210Open DOISearch in Google Scholar

2De Felice F, Piccioli A, Musio D, Tombolini V. The role of radiation therapy in bone metastases management. Oncotarget 2017; 8: 25691-9. doi: 10.18632/oncotarget.14823 De Felice F Piccioli A Musio D Tombolini V The role of radiation therapy in bone metastases management Oncotarget 2017 8 25691 9 10.18632/oncotarget.14823542196228148890Open DOISearch in Google Scholar

3Spencer KL, van der Velden JM, Wong E, Seravalli E, Sahgal A, Chow E, et al. Systematic review of the role of stereotactic radiotherapy for bone metastases. J Natl Cancer Inst 2019; 111: 1023-32. doi: 10.1093/jnci/djz101 Spencer KL van der Velden JM Wong E Seravalli E Sahgal A Chow E et al Systematic review of the role of stereotactic radiotherapy for bone metastases J Natl Cancer Inst 2019 111 1023 32 10.1093/jnci/djz101679207331119273Open DOISearch in Google Scholar

4Fornetti J, Welm AL, Stewart SA. Understanding the bone in cancer metastasis. J Bone Miner Res 2018; 33: 2099-113. doi: 10.1002/jbmr.3618 Fornetti J Welm AL Stewart SA Understanding the bone in cancer metastasis J Bone Miner Res 2018 33 2099 113 10.1002/jbmr.361830476357Open DOISearch in Google Scholar

5Pontoriero A, Lillo S, Caravatta L, Bellafiore F, Longo S, Lattanzi E, et al. Cumulative dose, toxicity, and outcomes of spinal metastases re-irradiation. Strahlenther Onkol 2021; 197: 369-84. doi: 10.1007/s00066-021-01748-7 Pontoriero A Lillo S Caravatta L Bellafiore F Longo S Lattanzi E et al Cumulative dose, toxicity, and outcomes of spinal metastases re-irradiation Strahlenther Onkol 2021 197 369 84 10.1007/s00066-021-01748-733635395Open DOISearch in Google Scholar

6Turpin A, Duterque-Coquillaud M, Vieillard MH. Bone metastasis: current state of play. Transl Oncol 2020; 13: 308-20. doi: 10.1016/j.tranon.2019.10.012 Turpin A Duterque-Coquillaud M Vieillard MH Bone metastasis: current state of play Transl Oncol 2020 13 308 20 10.1016/j.tranon.2019.10.012693119231877463Open DOISearch in Google Scholar

7Tang X, Hu Q, Chen Y, Wang X, Li X, Cheng K, et al. Optimal dose-fractionation schedule of palliative radiotherapy for patients with bone metastases: a protocol for systematic review and network meta-analysis. BMJ Open 2020; 10: e033120. doi: 10.1136/bmjopen-2019-033120 Tang X Hu Q Chen Y Wang X Li X Cheng K et al Optimal dose-fractionation schedule of palliative radiotherapy for patients with bone metastases: a protocol for systematic review and network meta-analysis BMJ Open 2020 10 e033120 10.1136/bmjopen-2019-033120695549231911518Open DOISearch in Google Scholar

8Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13: 8-10. doi: 10.1200/JCO.1995.13.1.8 Hellman S Weichselbaum RR Oligometastases J Clin Oncol 1995 13 8 10 10.1200/JCO.1995.13.1.87799047Open DOISearch in Google Scholar

9Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 2017; 14: 15-25. doi: 10.1038/nrurol.2016.175 Tosoian JJ Gorin MA Ross AE Pienta KJ Tran PT Schaeffer EM Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations Nat Rev Urol 2017 14 15 25 10.1038/nrurol.2016.175580841127725639Open DOISearch in Google Scholar

10Hurmuz P, Onal C, Ozyigit G, Igdem S, Atalar B, Sayan H, et al. Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002). Strahlenther Onkol 2020; 196: 1034-43. doi: 10.1007/s00066-020-01660-6 Hurmuz P Onal C Ozyigit G Igdem S Atalar B Sayan H et al Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002) Strahlenther Onkol 2020 196 1034 43 10.1007/s00066-020-01660-632617620Open DOISearch in Google Scholar

11Foster CC, Weichselbaum RR, Pitroda SP. Oligometastatic prostate cancer: Reality or figment of imagination? Cancer 2019; 125: 340-52. doi: 10.1002/cncr.31860 Foster CC Weichselbaum RR Pitroda SP Oligometastatic prostate cancer: Reality or figment of imagination? Cancer 2019 125 340 52 10.1002/cncr.31860658745830521067Open DOISearch in Google Scholar

12Palma DA, Salama JK, Lo SS, Senan S, Treasure T, Govindan R, et al. The oligometastatic state - separating truth from wishful thinking. Nat Rev Clin Oncol 2014; 11: 549-57. doi: 10.1038/nrclinonc.2014.96 Palma DA Salama JK Lo SS Senan S Treasure T Govindan R et al The oligometastatic state - separating truth from wishful thinking Nat Rev Clin Oncol 2014 11 549 57 10.1038/nrclinonc.2014.9624958182Open DOISearch in Google Scholar

13Fraser M, Koontz B, Emmenegger U, De Meerleer G, Khoo V, Feng F, et al. What is oligometastatic prostate cancer? Eur Urol Focus 2019; 5: 159-61. doi: 10.1016/j.euf.2018.12.009 Fraser M Koontz B Emmenegger U De Meerleer G Khoo V Feng F et al What is oligometastatic prostate cancer? Eur Urol Focus 2019 5 159 61 10.1016/j.euf.2018.12.00930642810Open DOISearch in Google Scholar

14Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 2018; 36: 446-53. doi: 10.1200/JCO.2017.75.4853 Ost P Reynders D Decaestecker K Fonteyne V Lumen N De Bruycker A et al Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial J Clin Oncol 2018 36 446 53 10.1200/JCO.2017.75.485329240541Open DOISearch in Google Scholar

15Hoskin PJ, Yarnold JR, Roos DR, Bentzen S, Second Workshop on Palliative R, Symptom C. Radiotherapy for bone metastases. Clin Oncol (R Coll Radiol) 2001; 13: 88-90. doi: 10.1053/clon.2001.9225 Hoskin PJ Yarnold JR Roos DR Bentzen S Second Workshop on Palliative R Symptom C Radiotherapy for bone metastases Clin Oncol (R Coll Radiol) 2001 13 88 90 10.1053/clon.2001.922511373885Open DOISearch in Google Scholar

16Rades D, Stalpers LJ, Veninga T, Schulte R, Hoskin PJ, Obralic N, et al. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol 2005; 23: 3366-75. doi: 10.1200/JCO.2005.04.754 Rades D Stalpers LJ Veninga T Schulte R Hoskin PJ Obralic N et al Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression J Clin Oncol 2005 23 3366 75 10.1200/JCO.2005.04.75415908648Open DOISearch in Google Scholar

17Jaffray D, Kupelian P, Djemil T, Macklis RM. Review of image-guided radiation therapy. Expert Rev Anticancer Ther 2007; 7: 89-103. doi: 10.1586/14737140.7.1.89 Jaffray D Kupelian P Djemil T Macklis RM Review of image-guided radiation therapy Expert Rev Anticancer Ther 2007 7 89 103 10.1586/14737140.7.1.8917187523Open DOISearch in Google Scholar

18Lee YK, Bedford JL, McNair HA, Hawkins MA. Comparison of deliverable IMRT and VMAT for spine metastases using a simultaneous integrated boost. Br J Radiol 2013; 86: 20120466. doi: 10.1259/bjr.20120466 Lee YK Bedford JL McNair HA Hawkins MA Comparison of deliverable IMRT and VMAT for spine metastases using a simultaneous integrated boost Br J Radiol 2013 86 20120466 10.1259/bjr.20120466360804323385999Open DOISearch in Google Scholar

19Lubgan D, Ziegaus A, Semrau S, Lambrecht U, Lettmaier S, Fietkau R. Effective local control of vertebral metastases by simultaneous integrated boost radiotherapy: preliminary results. Strahlenther Onkol 2015; 191: 264-71. doi: 10.1007/s00066-014-0780-4 Lubgan D Ziegaus A Semrau S Lambrecht U Lettmaier S Fietkau R Effective local control of vertebral metastases by simultaneous integrated boost radiotherapy: preliminary results Strahlenther Onkol 2015 191 264 71 10.1007/s00066-014-0780-425395089Open DOISearch in Google Scholar

20Guckenberger M, Mantel F, Sweeney RA, Hawkins M, Belderbos J, Ahmed M, et al. Long-term results of dose-intensified fractionated stereotactic body radiation therapy (SBRT) for painful spinal metastases. Int J Radiat Oncol Biol Phys 2021; 110: 348-57. doi: 10.1016/j.ijrobp.2020.12.045 Guckenberger M Mantel F Sweeney RA Hawkins M Belderbos J Ahmed M et al Long-term results of dose-intensified fractionated stereotactic body radiation therapy (SBRT) for painful spinal metastases Int J Radiat Oncol Biol Phys 2021 110 348 57 10.1016/j.ijrobp.2020.12.04533412262Open DOISearch in Google Scholar

21Sprave T, Welte SE, Bruckner T, Förster R, Bostel T, Schlampp I, et al. Intensity-modulated radiotherapy with integrated-boost in patients with bone metastasis of the spine: study protocol for a randomized controlled trial. Trials 2018; 19: 59. doi: 10.1186/s13063-018-2452-7 Sprave T Welte SE Bruckner T Förster R Bostel T Schlampp I et al Intensity-modulated radiotherapy with integrated-boost in patients with bone metastasis of the spine: study protocol for a randomized controlled trial Trials 2018 19 59 10.1186/s13063-018-2452-7577862829357902Open DOISearch in Google Scholar

22Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys 2010; 76(3 Suppl): S42-9. doi: 10.1016/j.ijrobp.2009.04.095 Kirkpatrick JP van der Kogel AJ Schultheiss TE Radiation dose-volume effects in the spinal cord Int J Radiat Oncol Biol Phys 2010 763 Suppl S42 9 10.1016/j.ijrobp.2009.04.09520171517Open DOISearch in Google Scholar

23de Vin T, Engels B, Gevaert T, Storme G, De Ridder M. Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. Ann Oncol 2014; 25: 467-71. doi: 10.1093/annonc/mdt537 de Vin T Engels B Gevaert T Storme G De Ridder M Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival Ann Oncol 2014 25 467 71 10.1093/annonc/mdt53724355488Open DOISearch in Google Scholar

24Guckenberger M, Mantel F, Gerszten PC, Flickinger JC, Sahgal A, Letourneau D, et al. Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis. Radiat Oncol 2014; 9: 226. doi: 10.1186/s13014-014-0226-2 Guckenberger M Mantel F Gerszten PC Flickinger JC Sahgal A Letourneau D et al Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis Radiat Oncol 2014 9 226 10.1186/s13014-014-0226-2420529225319530Open DOISearch in Google Scholar

25Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, et al. Palliative radiation therapy for bone metastases: update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol 2017; 7: 4-12. doi: 10.1016/j.prro.2016.08.001 Lutz S Balboni T Jones J Lo S Petit J Rich SE et al Palliative radiation therapy for bone metastases: update of an ASTRO Evidence-Based Guideline Pract Radiat Oncol 2017 7 4 12 10.1016/j.prro.2016.08.00127663933Open DOISearch in Google Scholar

26Fujino M, Suzuki K, Nishio M, Nishiyama N, Osaka Y. Strategy of radiation therapy for bone metastases and MSCC in breast cancer patients. Breast Cancer 2011; 18: 238-43. doi: 10.1007/s12282-011-0288-z Fujino M Suzuki K Nishio M Nishiyama N Osaka Y Strategy of radiation therapy for bone metastases and MSCC in breast cancer patients Breast Cancer 2011 18 238 43 10.1007/s12282-011-0288-z21814843Open DOISearch in Google Scholar

27Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M, 3rd, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005; 97: 798-804. doi: 10.1093/jnci/dji139 Hartsell WF Scott CB Bruner DW Scarantino CW Ivker RA Roach M 3rd, et al Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases J Natl Cancer Inst 2005 97 798 804 10.1093/jnci/dji13915928300Open DOISearch in Google Scholar

28Hölscher T, Baumann M, Kotzerke J, Wirth M, Thomas C, Zips D, et al. OLI-P: Toxicity and efficacy of local ablative radiotherapy in PSMA-PET staged, oli-gometastatic prostate cancer – a phase II trial. [abstract]. J Clin Oncol 2021; 39(6 Suppl): 115. doi: 10.1200/JCO.2021.39.6_suppl.115 Hölscher T Baumann M Kotzerke J Wirth M Thomas C Zips D et al OLI-P: Toxicity and efficacy of local ablative radiotherapy in PSMA-PET staged, oli-gometastatic prostate cancer – a phase II trial [abstract]. J Clin Oncol 2021 396 Suppl 115 10.1200/JCO.2021.39.6_suppl.115Open DOISearch in Google Scholar

29Rades D, Panzner A, Rudat V, Karstens JH, Schild SE. Dose escalation of radiotherapy for metastatic spinal cord compression (MSCC) in patients with relatively favorable survival prognosis. Strahlenther Onkol 2011; 187: 729-35. doi: 10.1007/s00066-011-2266-y Rades D Panzner A Rudat V Karstens JH Schild SE Dose escalation of radiotherapy for metastatic spinal cord compression (MSCC) in patients with relatively favorable survival prognosis Strahlenther Onkol 2011 187 729 35 10.1007/s00066-011-2266-y22037654Open DOISearch in Google Scholar

30Gerszten PC, Mendel E, Yamada Y. Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine 2009; 34(22 Suppl): S78-92. doi: 10.1097/BRS.0b013e3181b8b6f5 Gerszten PC Mendel E Yamada Y Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine 2009 3422 Suppl S78 92 10.1097/BRS.0b013e3181b8b6f519829280Open DOISearch in Google Scholar

31Makita K, Hamamoto Y, Kanzaki H, Kataoka M, Yamamoto S, Nagasaki K, et al. Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study. Radiat Oncol 2021; 16: 225. doi: 10.1186/s13014-021-01940-0 Makita K Hamamoto Y Kanzaki H Kataoka M Yamamoto S Nagasaki K et al Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study Radiat Oncol 2021 16 225 10.1186/s13014-021-01940-0860554934801042Open DOISearch in Google Scholar

32Sprave T, Verma V, Forster R, Schlampp I, Hees K, Bruckner T, et al. Bone density and pain response following intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for vertebral metastases – secondary results of a randomized trial. Radiat Oncol 2018; 13: 212. doi: 10.1186/s13014-018-1161-4 Sprave T Verma V Forster R Schlampp I Hees K Bruckner T et al Bone density and pain response following intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for vertebral metastases – secondary results of a randomized trial Radiat Oncol 2018 13 212 10.1186/s13014-018-1161-4620811530376859Open DOISearch in Google Scholar